ECSP109934A - Compuesto - 946 - Google Patents

Compuesto - 946

Info

Publication number
ECSP109934A
ECSP109934A EC2010009934A ECSP109934A ECSP109934A EC SP109934 A ECSP109934 A EC SP109934A EC 2010009934 A EC2010009934 A EC 2010009934A EC SP109934 A ECSP109934 A EC SP109934A EC SP109934 A ECSP109934 A EC SP109934A
Authority
EC
Ecuador
Prior art keywords
compound
pi13k
enzymes
cancer
therapy
Prior art date
Application number
EC2010009934A
Other languages
English (en)
Inventor
Kurt Gordon Pike
Maurice Raymond Verschoyle Finlay
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of ECSP109934A publication Critical patent/ECSP109934A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Un compuesto de fórmula(I) o una de sus sales farmacéuticamente aceptables del mismo, procesos para su preparación, composiciones farmacéuticas que los contienen y su uso en terapia, por ejemplo en el tratamiento de enfermedades proliferativas tal como cáncer y particularmente una enfermedades mediadas por una quinasa mTOR y una o más enzimas PI13K.
EC2010009934A 2007-07-09 2010-02-03 Compuesto - 946 ECSP109934A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US94857007P 2007-07-09 2007-07-09

Publications (1)

Publication Number Publication Date
ECSP109934A true ECSP109934A (es) 2010-03-31

Family

ID=40029122

Family Applications (1)

Application Number Title Priority Date Filing Date
EC2010009934A ECSP109934A (es) 2007-07-09 2010-02-03 Compuesto - 946

Country Status (17)

Country Link
US (1) US20100227858A1 (es)
EP (1) EP2176256A2 (es)
JP (1) JP2010533161A (es)
KR (1) KR20100042643A (es)
CN (1) CN101801963A (es)
AU (1) AU2008273892A1 (es)
BR (1) BRPI0814503A2 (es)
CA (1) CA2692725A1 (es)
CO (1) CO6251271A2 (es)
CR (1) CR11199A (es)
DO (1) DOP2010000013A (es)
EA (1) EA201000090A1 (es)
EC (1) ECSP109934A (es)
NI (1) NI201000003A (es)
SV (1) SV2010003451A (es)
WO (1) WO2009007751A2 (es)
ZA (1) ZA201000087B (es)

Families Citing this family (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101809002B (zh) 2007-07-09 2013-03-27 阿斯利康(瑞典)有限公司 用于与mtor激酶和/或pi3k相关的疾病中的吗啉代嘧啶衍生物
CA2725014C (en) 2008-05-30 2014-06-17 Amgen Inc. Inhibitors of pi3 kinase
US20110053923A1 (en) * 2008-12-22 2011-03-03 Astrazeneca Chemical compounds 610
ES2529205T3 (es) 2009-03-13 2015-02-17 Cellzome Limited Derivados de pirimidina como inhibidores de mTOR
UY32582A (es) 2009-04-28 2010-11-30 Amgen Inc Inhibidores de fosfoinositida 3 cinasa y/u objetivo mamífero
SG10201402867TA (en) 2009-07-02 2014-08-28 Sanofi Sa Novel (6-oxo-1, 6-dihydro-pyrimidin-2-yl)-amide derivatives, preparation thereof, and pharmaceutical use thereof as akt(pkb) phosphorylation inhibitors
WO2011001115A1 (fr) 2009-07-02 2011-01-06 Sanofi-Aventis Nouveaux derives de 6-morpholin-4-yl-pyrimidin-4- ( 3h ) -one, leur preparation pharmaceutique comme inhibiteurs de phos phorylat i on d ' akt ( pkb )
JP2013509444A (ja) 2009-10-30 2013-03-14 アリアド・ファーマシューティカルズ・インコーポレイテッド がんの治療方法及び治療用組成物
CA2788678C (en) 2010-02-03 2019-02-26 Signal Pharmaceuticals, Llc Identification of lkb1 mutation as a predictive biomarker for sensitivity to tor kinase inhibitors
EP2542536B1 (en) 2010-03-04 2015-01-21 Cellzome Limited Morpholino substituted urea derivatives as mtor inhibitors
SA111320519B1 (ar) * 2010-06-11 2014-07-02 Astrazeneca Ab مركبات بيريميدينيل للاستخدام كمثبطات atr
EP2604601B1 (en) 2010-08-10 2016-02-24 Astellas Pharma Inc. Hetero ring compound
US9133168B2 (en) 2010-12-28 2015-09-15 Sanofi Pyrimidine derivatives, preparation thereof, and pharmaceutical use thereof as akt(pkb) phosphorylation inhibitors
TWI572599B (zh) 2011-03-28 2017-03-01 Ｍｅｉ製藥公司 （α－經取代之芳烷胺基及雜芳烷胺基）嘧啶基及１，３，５－三基苯并咪唑，其醫藥組合物及其在治療增生性疾病之用途
WO2012136622A1 (en) 2011-04-04 2012-10-11 Cellzome Limited Dihydropyrrolo pyrimidine derivatives as mtor inhibitors
MX370455B (es) 2011-07-27 2019-12-13 Bayer Ip Gmbh Ácidos picolínicos y piridimin-4-carboxílicos sustituidos, procedimiento para su preparación y su uso como herbicidas y reguladores del crecimiento de plantas.
HK1199068A1 (en) 2011-08-03 2015-06-19 西格诺药品有限公司 Identification of gene expression profile as a predictive biomarker for lkb1 status
EP3255041A1 (en) 2011-09-02 2017-12-13 Purdue Pharma L.P. Pyrimidines as sodium channel blockers
WO2013041652A1 (en) 2011-09-21 2013-03-28 Cellzome Limited Morpholino substituted urea or carbamate derivatives as mtor inhibitors
KR20140084130A (ko) 2011-10-07 2014-07-04 셀좀 리미티드 Mtor 억제제로서의 모르폴리노 치환된 바이사이클릭 피리미딘 우레아 또는 카르바메이트 유도체
AU2013203714B2 (en) 2012-10-18 2015-12-03 Signal Pharmaceuticals, Llc Inhibition of phosphorylation of PRAS40, GSK3-beta or P70S6K1 as a marker for TOR kinase inhibitory activity
US9637505B2 (en) 2013-03-15 2017-05-02 Dow Agrosciences Llc 4-amino-6-(heterocyclic)picolinates and 6-amino-2-(heterocyclic)pyrimidine-4-carboxylates and their use as herbicides
CA2908742C (en) 2013-04-17 2021-06-01 Signal Pharmaceuticals, Llc Combination therapy comprising a tor kinase inhibitor and a cytidine analog for treating cancer
CA2909629C (en) 2013-04-17 2022-12-13 Signal Pharmaceuticals, Llc Pharmaceutical formulations, processes, solid forms and methods of use relating to 1-ethyl-7-(2-methyl-6-(1h-1,2,4-triazol-3-yl)pyridin-3-yl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1h)-one
WO2014172436A1 (en) 2013-04-17 2014-10-23 Signal Pharmaceuticals, Llc Combination therapy comprising a tor kinase inhibitor and a 5-substituted quinazolinone compound for treating cancer
CA2909579A1 (en) 2013-04-17 2014-10-23 Signal Pharmaceuticals, Llc Combination therapy comprising a tor kinase inhibitor and n-(3-(5-fluoro-2-(4-(2-methoxyethoxy)phenylamino)pyrimidin-4-ylamino)phenyl)acrylamide for treating cancer
US9505764B2 (en) 2013-04-17 2016-11-29 Signal Pharmaceuticals, Llc Treatment of cancer with dihydropyrazino-pyrazines
CN105377299B (zh) 2013-04-17 2018-06-12 西格诺药品有限公司 用于治疗前列腺癌的包含二氢吡嗪并-吡嗪化合物和雄激素受体拮抗剂的组合疗法
US9630966B2 (en) 2013-04-17 2017-04-25 Signal Pharmaceuticals, Llc Treatment of cancer with dihydropyrazino-pyrazines
NZ629486A (en) 2013-05-29 2017-11-24 Signal Pharm Llc Pharmaceutical compositions of 7-(6-(2-hydroxypropan-2-yl)pyridin-3-yl)-1-((trans)-4-methoxycyclohexyl)-3,4-dihydropyrazino [2,3-b]pyrazin-2(1h)-one, a solid form thereof and methods of their use
ES2693718T3 (es) 2013-11-06 2018-12-13 Bristol-Myers Squibb Company Derivados de piridina sustituidos útiles como inhibidores de GSK-3
AU2014347027A1 (en) 2013-11-06 2016-06-23 Bristol-Myers Squibb Company GSK -3 inhibitors
US9512129B2 (en) 2014-04-16 2016-12-06 Signal Pharmaceuticals, Llc Solid forms comprising 1-ethyl-7-(2-methyl-6-(1H-1,2,4-triazol-3-yl)pyridin-3-yl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1H)-one and a coformer
NZ714742A (en) 2014-04-16 2017-04-28 Signal Pharm Llc Solid forms of 1-ethyl-7-(2-methyl-6-(1h-1,2,4-triazol-3-yl)pyridin-3-yl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1h)-one, compositions thereof and methods of their use
CR20170077A (es) 2014-08-04 2017-06-26 Nuevolution As Derivados de heterociclilo opcionalmente condensados de pirimidina útiles para el tratamiento de enfermedades inflamatorias, metabólicas, oncológicas y autoinmunitarias
WO2016022890A1 (en) 2014-08-08 2016-02-11 Duquesne University Of The Holy Spirit Pyrimidine compounds and pyrimido indole compounds and methods of use
EP3193607A4 (en) 2014-09-15 2018-05-02 Dow AgroSciences LLC Synergistic weed control from applications of pyridine carboxylic acid herbicides and photosystem ii inhibitors
AR101858A1 (es) 2014-09-15 2017-01-18 Dow Agrosciences Llc Composiciones herbicidas protegidas que comprenden un herbicida de ácido piridincarboxílico
TWI685302B (zh) 2014-09-15 2020-02-21 美商陶氏農業科學公司 包含吡啶羧酸除草劑之安全的除草組成物
TWI689251B (zh) 2014-09-15 2020-04-01 美商陶氏農業科學公司 源自於施用吡啶羧酸除草劑與合成生長素除草劑及/或生長素轉運抑制劑的協同性雜草控制
TWI689252B (zh) 2014-09-15 2020-04-01 美商陶氏農業科學公司 源自於施用吡啶羧酸除草劑與乙醯乳酸合成酶（ａｌｓ）抑制劑的協同性雜草控制
AU2016315665B2 (en) * 2015-09-01 2019-07-18 Baker Hughes, A Ge Company, Llc Method of improving mobility of heavy crude oils in subterranean reservoirs
WO2018146079A1 (de) 2017-02-13 2018-08-16 Bayer Cropscience Aktiengesellschaft Substituierte benzyl-4-aminopicolinsäureester und pyrimidin-4-carbonsäureester, verfahren zu deren herstellung sowie deren verwendung als herbizide und pflanzenwachstumsregulatoren
EP3360872A1 (de) 2017-02-13 2018-08-15 Bayer CropScience Aktiengesellschaft Unsubstituierte benzyl-4-aminopicolinsäureester und pyrimidin-4-carbonsäureester, verfahren zu deren herstellung sowie deren verwendung als herbizide und pflanzenwachstumsregulatoren
US11304953B2 (en) 2017-05-23 2022-04-19 Mei Pharma, Inc. Combination therapy
WO2018218197A2 (en) 2017-05-26 2018-11-29 Board Of Regents, The University Of Texas System Tetrahydropyrido[4,3-d]pyrimidine inhibitors of atr kinase
TWI787284B (zh) 2017-06-22 2022-12-21 美商西建公司 以b型肝炎病毒感染表徵之肝細胞癌之治療
WO2019014618A1 (en) 2017-07-13 2019-01-17 Board Of Regents, University Of Texas System HETEROCYCLIC INHIBITORS OF KINASE ATR
KR20200041358A (ko) 2017-08-14 2020-04-21 메이 파마, 아이엔씨. 병용 요법
JP7290627B2 (ja) 2017-08-17 2023-06-13 ボード オブ レジェンツ，ザ ユニバーシティ オブ テキサス システム Ａｔｒキナーゼの複素環式阻害剤
GB201720989D0 (en) * 2017-12-15 2018-01-31 Glaxosmithkline Ip Dev Ltd Chemical compounds
JP7341156B2 (ja) * 2018-03-16 2023-09-08 ボード オブ レジェンツ，ザ ユニバーシティ オブ テキサス システム Ａｔｒキナーゼの複素環式阻害剤
AU2019373416A1 (en) 2018-10-30 2021-06-10 Repare Therapeutics Inc. Compounds, pharmaceutical compositions, and methods of preparing compounds and of their use as ATR kinase inhibitors
CN118619944A (zh) 2019-06-06 2024-09-10 北京泰德制药股份有限公司 作为atr激酶抑制剂的2,4,6-三取代的嘧啶化合物
GB201908536D0 (en) * 2019-06-13 2019-07-31 Glaxosmithkline Ip Dev Ltd Compounds
UY38994A (es) 2019-12-20 2021-07-30 Nuevolution As Compuestos activos frente a receptores nucleares
MX2022007265A (es) 2019-12-20 2022-09-09 Nuevolution As Compuestos activos frente a receptores nucleares.
WO2021198956A1 (en) 2020-03-31 2021-10-07 Nuevolution A/S Compounds active towards nuclear receptors
AU2021245397A1 (en) 2020-03-31 2022-10-20 Nuevolution A/S Compounds active towards nuclear receptors

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS60222160A (ja) * 1984-04-20 1985-11-06 Hitachi Constr Mach Co Ltd 破壊機における散水装置
DE3922735A1 (de) * 1989-07-11 1991-01-24 Hoechst Ag Aminopyrimidin-derivate, verfahren zu ihrer herstellung, sie enthaltende mittel und ihre verwendung als fungizide
CN1473156A (zh) * 2000-11-10 2004-02-04 - 嘧啶衍生物及其作为神经肽y受体配体的用途
US7772271B2 (en) * 2004-07-14 2010-08-10 Ptc Therapeutics, Inc. Methods for treating hepatitis C
WO2006124874A2 (en) * 2005-05-12 2006-11-23 Kalypsys, Inc. Inhibitors of b-raf kinase
WO2007027855A2 (en) * 2005-09-01 2007-03-08 Array Biopharma Inc. Raf inhibitor compounds and methods of use thereof
GB0520657D0 (en) * 2005-10-11 2005-11-16 Ludwig Inst Cancer Res Pharmaceutical compounds
GB0525083D0 (en) * 2005-12-09 2006-01-18 Astrazeneca Ab Pyrimidine derivatives
EP1979325A1 (en) * 2006-01-11 2008-10-15 AstraZeneca AB Morpholino pyrimidine derivatives and their use in therapy
EP2146981A1 (en) * 2007-04-12 2010-01-27 F. Hoffmann-Roche AG Pharmaceutical compounds

Also Published As

Publication number Publication date
SV2010003451A (es) 2010-06-09
BRPI0814503A2 (pt) 2017-05-16
CO6251271A2 (es) 2011-02-21
WO2009007751A3 (en) 2009-04-23
US20100227858A1 (en) 2010-09-09
CR11199A (es) 2010-06-17
AU2008273892A1 (en) 2009-01-15
EA201000090A1 (ru) 2010-06-30
ZA201000087B (en) 2011-06-29
CN101801963A (zh) 2010-08-11
DOP2010000013A (es) 2010-01-31
KR20100042643A (ko) 2010-04-26
JP2010533161A (ja) 2010-10-21
NI201000003A (es) 2010-10-12
WO2009007751A2 (en) 2009-01-15
CA2692725A1 (en) 2009-01-15
EP2176256A2 (en) 2010-04-21

Similar Documents

Publication Publication Date Title
ECSP109934A (es) Compuesto - 946
CO6390066A2 (es) Derivados de pirimidina trisustituida para el tratamiento de enfermedades proliferativas
CR11200A (es) Derivados de morfolino pirimidina utilizados en enfermedades relacionadas con mtor quinasa y/o p13k
UY30559A1 (es) Derivados de morfolino pirimidina, procesos de preparacion, composiciones conteniéndolos y aplicaciones
CL2011003082A1 (es) Compuestos derivados de [1,2,4]triazolo[1,5-a]piridina, inhibidores de jak2 o fak; composiciones farmaceuticas que los comprenden; y su uso para el tratamiento de una enfermedad hiperproliferativa.
UY32158A (es) Derivados heterociclicos y metodos de uso de los mismos
DOP2011000203A (es) Derivados de pirimidin indol para el tratamiento de cancer
ECSP11011113A (es) Piridiloxi-indoles inhibidores del vegf-r2 y uso de los mismos para el tratamiento de enfermedades
UY33480A (es) Compuestos terapeuticos, composicion farmaceutica que lo comprende, metodo de tratamiento y su uso para la manufactura de un medicamento.
UY36285A (es) Compuestos que inhiben la proteína mcl-1
UY29199A1 (es) Derivados tiazol, composiciones que los contienen, procedimientos de preparación y aplicaciones
UY31918A (es) Compuestos de pirazol inhibidores de fgfr, composiciones farmaceuticas que los comprenden, procesos para su preparacion y su uso como medicamento
MX2016010519A (es) Moleculas para administracion a celulas cancerosas mutantes ros1.
DOP2010000259A (es) Derivados heterociclicos de urea y metodos de uso de los mismos-211
UY30819A1 (es) Derivados de pirazol, composiciones farmacéuticas conteniéndolos, procesos de preparacion y aplicaciones
ECSP088329A (es) Nuevos diazaespiroalcanos y su uso para el tratamiento de enfermedades mediadas por ccr8
UY30846A1 (es) Derivados de oxindol sustituidos, medicamentos que los comprenden y uso de los mismos
ECSP088828A (es) 4-anilinoquinolina-3-carboxamidas como inhibidores de la quinasa csf-1r
UY32315A (es) Compuestos de piperidina y usos de los mismo-596
UY31141A1 (es) Compuestos de piperidina y sus usos
UY32190A (es) Derivados de anilina-pirimidina sustituidos con sulfoximina como inhibdores de quinasas dependientes de ciclina (cdk), produccion y uso de los mismos como productos medicinales
UY32674A (es) Derivados heterociclicos de la urea y sus metodos de empleo
UY29561A1 (es) Derivados de quinazolina, composiciones farmacéuticas que los contienen, procedimientos de preparación y aplicaciones
ECSP10010389A (es) Pirimidil ciclopentanos hidroxilados en forma de inhibidores de akt proteina quinasa
CL2007003251A1 (es) Compuestos derivados de 1h-pirazoles sustituidos, inhibidores de reacciones catalizadas por una quinasa; su procedimiento de preparacion; composicion farmaceutica; compuestos intermediarios; uso de los compuestos principales, utiles en el tratamiento del cancer.